Argenta today announced that the company’s Board of Directors has appointed Will Downie as Chief Executive Officer, effective immediately. Will Downie succeeds interim CEO Stephen Sibson, who will resume his role as Argenta’s Global Head of Manufacturing.

“I am delighted to have accepted the role of CEO of Argenta and to have the opportunity to be part of the world’s only integrated CRO/CDMO animal health company. I am particularly excited about helping the organisation to build on its ‘Molecule to Market’ strategy, as well as accelerating innovation to drive sustained business growth for the benefit of Argenta’s customers, employees, and shareholders,” said Will Downie.

Will has extensive leadership experience in the healthcare industry. Prior to joining Argenta, Will was the CEO of Vectura Group plc, where he spearheaded the transformation of the business into a global leader in the inhaled CDMO space, almost doubling the market capitalisation of the company to £1.1 billion. Before Vectura, Will was the Chief Commercial Officer at Catalent Inc. for ten years, where he helped drive the long-term growth of the company and positioned the brand as one of the leaders in the pharmaceutical outsourcing space. 

“We are very pleased that Will has accepted the position of Argenta’s new CEO. He has highly relevant experience that we believe will add great value to the business, as well as a demonstrated ability in building successful organisations. We are confident that he will be a force in developing and driving Argenta forward at what is an exciting time in the animal health industry. The Board wants to offer their sincere thanks to Stephen Sibson for his committed leadership during his time as interim CEO while we completed the search process,” said George Gunn, Chairman of the Board.

‍

About Argenta

Argenta is the only combined global Contract Research Organisation (CRO) and Contract Development and Manufacturing Organisation (CDMO) dedicated to animal health. Founded in 2006 in New Zealand, Argenta’s talented, diverse, and committed employees are driven to deliver excellence in animal health to customers around the world. With research and GMP manufacturing operations in New Zealand, the United States, the United Kingdom, and Germany, Argenta operates from ‘Molecule to Market’ in partnership with its customers to support their R&D, regulatory, pre-clinical and clinical research, and manufacturing needs along the veterinary product development journey. For more information about Argenta, please visit www.argentaglobal.com.

‍

Press Contact

Annemieke de Keijzer

+1 732-439-3446

globalcommunications@argentaglobal.com

‍